CCRM
Umar Owadally is a dedicated professional in the field of quality assurance and regulatory affairs, currently serving as a Quality Assurance Associate II at CCRM since May 2022. Prior experience includes working as a Quality Assurance Associate at Eurofins from February 2020 to May 2022, and a Regulatory Affairs Associate at SteriMax Inc. in the summer of 2019. Educational qualifications include a Bachelor of Science in Pharmacology and Toxicology from the University of Toronto and a Post Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca Polytechnic. Umar Owadally also held notable positions such as Research Assistant at the University of Toronto and Co-President of iGEM Toronto, along with experience as a Manufacturing Technology Technician Co-Op at Sanofi Pasteur.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.